Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data
Company Posts Solid Q2 Sales Despite REGEN-COV Drop
The costimulatory bispecific antibody REGN5678, meant to turn “cold” prostate cancer tumors “hot” and vulnerable to PD-1 inhibitors, showed early signs of efficacy combined with Libtayo.
You may also be interested in...
Libtayo Gains Approval for First-Line NSCLC With Chemotherapy
Regeneron's PD-1 inhibitor was approved by the US FDA in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer.
Regeneron Gets Encouraging Early Data For Bispecifics In Solid Tumors
The company presented positive early data at ESMO for two bispecific antibodies that are important to the company's long-term business strategy, MUC16xCD3 and METxMET.
As Jounce’s Vopratelimab Fails, Door Opens For LILRB2 Inhibitor JTX-8064
Vopratelimab is the second major ICOS agonist program to fail since GSK halted studies of feladilimab last year, but an analyst pinned higher hopes on JTX-8064.